Back to search results

MaMa: Maternal Mental Health Access for Perinatal Depression

This study, called MaMa, is testing different ways to deliver a program called UPLIFT to help prevent postpartum depression and perinatal depression (depression during or after pregnancy). UPLIFT uses Mindfulness-Based Cognitive Behavioral Therapy (MBCT), which teaches skills to manage thoughts and feelings. The study is looking at how easy it is to offer UPLIFT through online methods, like on-demand videos and online discussion boards, or video calls. You might be able to join if you are 18 or older, pregnant or up to one year postpartum, and at risk for depression. The study aims to enroll 120 women and will check how well the program is received and used over 6, 12, and 18 months.

Study design
This is an interventional study planning to enroll 120 participants. It uses a randomized preference design to evaluate different ways of delivering the UPLIFT program.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for implementation outcomes, feasibility, and acceptability at 6, 12, and 18 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06049433

Maternal Mental Health Access - MaMa

Recruiting
NAAges 18+InterventionalSupportive care
University of Utah
~120 participants
Updated 2024-12-06 on ClinicalTrials.gov
What's tested:Maternal Mental Health Access for Postpartum Depression- Prevention and UPLIFT- interventionOn-Demand + Discussion board (DB)Arm 2On Demand (OD) + Video Conference (VC)Arm 3

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Implementation outcome; Feasibility and acceptability
Measured over (6, 12 & 18 months)

Conditions

Postpartum Depression
Perinatal Depression

Explore related trials

Perinatal DepressionPostpartum Depression

Where it's being run

1 sites across 1 states
Utah1

Study leadership

  • Gwen Latendresse · PRINCIPAL_INVESTIGATOR · University of Utah

Who to contact

Gwen Latendresse, PhD CNM
[email protected]
(801) 587-9636
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18+ years of age, who at the time of screening
Have a viable pregnancy or are postpartum (up to 1 year)
Identified as at-risk for PD (any one of the following:
EPDS score equal to or greater than 9 or less than 21
History of depression/anxiety
2 or more significant life events)
English- or Spanish-speaking
Currently attending a UHealth clinic or rural public health partner clinic.

Exclusion

Have a substance use disorder
Current diagnosis of serious mental illness, such as psychosis, schizophrenia, bipolar disorder, severe depression (including EPDS \> 20)
Severe anxiety, suicidality, or currently taking any medications for a mental health condition.

What this trial measures

  • Implementation outcome; Feasibility and acceptability(6, 12 & 18 months)

    EPDS Scores are between 0 and 30, with scores 13 and above indicating depressive illness, or a high risk of developing a depressive disorder. Using scores that are between 9-20 Qualitative; semi structured interview Quantitative; patient satisfaction survey, number of referrals for at-risk patients, patients registering on YoMingo. focus groups, individual interviews, questionnaires